Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;17(5):313-314.
doi: 10.1038/s41569-020-0369-9.

Reply To: 'Interaction Between RAAS Inhibitors and ACE2 in the Context of COVID-19'

Free PMC article

Reply To: 'Interaction Between RAAS Inhibitors and ACE2 in the Context of COVID-19'

Ying-Ying Zheng et al. Nat Rev Cardiol. .
Free PMC article

Conflict of interest statement

The authors declare no competing interests.

Comment on

Similar articles

See all similar articles

Cited by 3 articles


    1. Mourad J-J, Levy BI. Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat. Rev. Cardiol. 2020
    1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020
    1. Ferrario CM, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605–2610. - PubMed
    1. Li Y, et al. Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation. Shock. 2015;43:395–404. - PubMed
    1. Wösten-van Asperen RM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1–7) or an angiotensin II receptor antagonist. J. Pathol. 2011;225:618–627. - PubMed


Supplementary concepts